23:09 , Feb 26, 2019 |  BC Extra  |  Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

CytomX Therapeutics Inc. (NASDAQ:CTMX) lost $6.03 (32%) to $13.13 on Tuesday after reporting severe toxicity signals with its CD166 Probody-drug conjugate, and disclosing that partner Bristol-Myers Squibb Co. (NYSE:BMY) terminated three targets under their discovery...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
18:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Pfizer ends PDC deal with CytomX

CytomX Therapeutics Inc. (NASDAQ:CTMX) disclosed in its 4Q17 earnings that it received notification that Pfizer Inc. (NYSE:PFE) plans to terminate a 2013 deal to develop and commercialize up to four Probody drug conjugate candidates using...
19:47 , Oct 13, 2017 |  BC Week In Review  |  Company News

Cellectar and Pierre Fabre extend PDC deal

Cellectar Biosciences Inc. (NASDAQ:CLRB) and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC) to treat cancer. The companies said the extension will cover combining Pierre Fabre's cytotoxic payloads...
19:07 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

CytomX begins Phase I/II of CX-2009 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC (CX-2009) in about 150 patients with metastatic or locally advanced unresectable solid tumors. The trial will recruit patients with...
17:16 , Dec 9, 2016 |  BC Week In Review  |  Financial News

PDC*line completes venture financing

PDC*line raised €4 million ($4.3 million) in a series A round from Meusinvest, Spinventure, Luxembourgeoise and angel investors. The round comprises €2.6 million ($2.8 million) in capital and €1.4 million ($1.5 million) in debt. PDC*line...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Probodies, anticancer

Lauren Martz, Senior Writer  How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities....
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Adjuvant Toll-like receptor 9 (TLR9) In vitro, mouse and primate studies suggest a CpG DNA nanoparticle wrapped in the polysaccharide schizophyllan could be used as...
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phosducin-like 3 (PDCL3); VEGF receptor 2 (KDR/Flk-1; VEGFR-2) Cell culture studies suggest inhibiting PDCL3 could help treat VEGFR-2-dependent angiogenesis in...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Toll-like receptor 7 (TLR7) Mouse studies suggest stimulating TLR7 on plasmacytoid dendritic cells (pDCs) could help treat breast cancer....